News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis recruits Katayoun Welin-Berger as Vice President Operations

January 27, 2023

Stockholm, Sweden, January 27, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the recruitment of Katayoun Welin-Berger, PhD, as Vice President Operations effective March 2023. Katayoun will be a member of the Company’s leadership team.

Katayoun has 30 years of experience in the pharmaceutical, probiotics and dietary supplements industries. She has a broad experience from roles of increasing responsibilities in areas including product development, CMC documentation, GMP manufacturing, procurement, outsourcing, supplier management, divestment, supply chain management and product life-cycle management. Prior to joining Egetis, Katayoun was Vice President Operations at Calliditas Therapeutics with the responsibility of designing and managing the supply chains for development candidates and commercial products, and previously she held a similar role at BioGaia.  Katayoun began her career in the pharmaceutical industry at AstraZeneca and held several positions within both R&D and Operations. She obtained a PhD in Pharmacy from Uppsala University.
Nicklas Westerholm, CEO of Egetis, commented:I’m delighted to welcome Katayoun to Egetis. Her extensive experience and knowledge in pharmaceutical operations all the way from product development to life-cycle management of commercial products makes her an ideal candidate for this position. She will be responsible for the setup of the entire supply chains of our current development candidates and future commercial products with focus on ensuring a successful launch of Emcitate in US and Europe during 2024.”



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10